nodes	percent_of_prediction	percent_of_DWPC	metapath
Riluzole—amyotrophic lateral sclerosis—multiple sclerosis	0.778	1	CtDrD
Riluzole—ABCG2—Cladribine—multiple sclerosis	0.0458	0.362	CbGbCtD
Riluzole—ABCG2—Mitoxantrone—multiple sclerosis	0.0334	0.264	CbGbCtD
Riluzole—ABCG2—Dexamethasone—multiple sclerosis	0.0173	0.137	CbGbCtD
Riluzole—CYP1A1—Dexamethasone—multiple sclerosis	0.016	0.126	CbGbCtD
Riluzole—ABCG2—Methotrexate—multiple sclerosis	0.0139	0.11	CbGbCtD
Riluzole—SLC7A11—Amino acid and oligopeptide SLC transporters—SLC15A2—multiple sclerosis	0.000736	0.0702	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—SELPLG—multiple sclerosis	0.000515	0.049	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—MERTK—multiple sclerosis	0.000515	0.049	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—CD58—multiple sclerosis	0.000515	0.049	CbGpPWpGaD
Riluzole—SLC7A11—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC15A2—multiple sclerosis	0.000434	0.0413	CbGpPWpGaD
Riluzole—SCN5A—L1CAM interactions—CD24—multiple sclerosis	0.000412	0.0393	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—PLP1—multiple sclerosis	0.000329	0.0313	CbGpPWpGaD
Riluzole—ABCG2—Irinotecan Pathway—BCHE—multiple sclerosis	0.000294	0.028	CbGpPWpGaD
Riluzole—ABCG2—Fluoropyrimidine Activity—RRM1—multiple sclerosis	0.000258	0.0246	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—SELE—multiple sclerosis	0.000224	0.0213	CbGpPWpGaD
Riluzole—SLC7A11—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000194	0.0185	CbGpPWpGaD
Riluzole—SLC7A11—Betamethasone—Methylprednisolone—multiple sclerosis	0.00019	0.105	CbGdCrCtD
Riluzole—SLC7A11—Dexamethasone—Methylprednisolone—multiple sclerosis	0.00019	0.105	CbGdCrCtD
Riluzole—SLC7A11—Dexamethasone—Betamethasone—multiple sclerosis	0.000187	0.104	CbGdCrCtD
Riluzole—SLC7A11—Betamethasone—Dexamethasone—multiple sclerosis	0.000187	0.104	CbGdCrCtD
Riluzole—SLC7A11—Betamethasone—Triamcinolone—multiple sclerosis	0.000183	0.101	CbGdCrCtD
Riluzole—SLC7A11—Dexamethasone—Triamcinolone—multiple sclerosis	0.000183	0.101	CbGdCrCtD
Riluzole—SLC7A11—Dexamethasone—Prednisone—multiple sclerosis	0.000173	0.0961	CbGdCrCtD
Riluzole—SLC7A11—Betamethasone—Prednisone—multiple sclerosis	0.000173	0.0961	CbGdCrCtD
Riluzole—SLC7A11—Dexamethasone—Prednisolone—multiple sclerosis	0.000169	0.0938	CbGdCrCtD
Riluzole—SLC7A11—Betamethasone—Prednisolone—multiple sclerosis	0.000169	0.0938	CbGdCrCtD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—ITGA4—multiple sclerosis	0.000162	0.0154	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—CD24—multiple sclerosis	0.000156	0.0149	CbGpPWpGaD
Riluzole—SLC7A11—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.000147	0.014	CbGpPWpGaD
Riluzole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000143	0.0137	CbGpPWpGaD
Riluzole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000143	0.0137	CbGpPWpGaD
Riluzole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000143	0.0136	CbGpPWpGaD
Riluzole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000143	0.0136	CbGpPWpGaD
Riluzole—CYP1A1—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000141	0.0134	CbGpPWpGaD
Riluzole—CYP1A1—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000141	0.0134	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—CD58—multiple sclerosis	0.00014	0.0133	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—SELPLG—multiple sclerosis	0.00014	0.0133	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—MERTK—multiple sclerosis	0.00014	0.0133	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—C4A—multiple sclerosis	0.000137	0.013	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.000122	0.0117	CbGpPWpGaD
Riluzole—CYP1A1—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000116	0.011	CbGpPWpGaD
Riluzole—CYP1A1—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000116	0.011	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—CD24—multiple sclerosis	0.000111	0.0106	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—AQP4—multiple sclerosis	0.000104	0.00986	CbGpPWpGaD
Riluzole—SLC7A11—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.000103	0.00978	CbGpPWpGaD
Riluzole—SLC7A11—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	9.85e-05	0.00938	CbGpPWpGaD
Riluzole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	9.1e-05	0.00867	CbGpPWpGaD
Riluzole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	9.1e-05	0.00867	CbGpPWpGaD
Riluzole—CYP1A2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	8.98e-05	0.00856	CbGpPWpGaD
Riluzole—CYP1A2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	8.98e-05	0.00856	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—PLEK—multiple sclerosis	8.62e-05	0.00822	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	7.8e-05	0.00744	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	7.69e-05	0.00732	CbGpPWpGaD
Riluzole—SLC7A11—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	7.46e-05	0.00711	CbGpPWpGaD
Riluzole—CYP1A2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	7.38e-05	0.00703	CbGpPWpGaD
Riluzole—CYP1A2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	7.38e-05	0.00703	CbGpPWpGaD
Riluzole—CYP1A1—Estrogen Receptor Pathway—STAT3—multiple sclerosis	6.79e-05	0.00647	CbGpPWpGaD
Riluzole—CYP1A1—Melatonin metabolism and effects—APOE—multiple sclerosis	6.69e-05	0.00637	CbGpPWpGaD
Riluzole—CYP1A1—Biological oxidations—CYP24A1—multiple sclerosis	6.15e-05	0.00586	CbGpPWpGaD
Riluzole—CYP1A1—Biological oxidations—CYP27B1—multiple sclerosis	6.15e-05	0.00586	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—SELE—multiple sclerosis	6.07e-05	0.00579	CbGpPWpGaD
Riluzole—CYP1A1—Metapathway biotransformation—CYP27B1—multiple sclerosis	6.06e-05	0.00578	CbGpPWpGaD
Riluzole—CYP1A1—Metapathway biotransformation—CYP24A1—multiple sclerosis	6.06e-05	0.00578	CbGpPWpGaD
Riluzole—SLC7A11—Transmembrane transport of small molecules—AQP4—multiple sclerosis	5.9e-05	0.00562	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	5.36e-05	0.0051	CbGpPWpGaD
Riluzole—SLC7A11—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	5.22e-05	0.00497	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—PRNP—multiple sclerosis	5.14e-05	0.0049	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—IL10—multiple sclerosis	5.11e-05	0.00487	CbGpPWpGaD
Riluzole—SCN5A—Cardiac Progenitor Differentiation—TGFB1—multiple sclerosis	4.94e-05	0.00471	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	4.9e-05	0.00467	CbGpPWpGaD
Riluzole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	4.69e-05	0.00447	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—ITGA4—multiple sclerosis	4.39e-05	0.00419	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—IFNB1—multiple sclerosis	4.36e-05	0.00415	CbGpPWpGaD
Riluzole—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	4.33e-05	0.00413	CbGpPWpGaD
Riluzole—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	4.26e-05	0.00406	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—PTPRC—multiple sclerosis	4e-05	0.00381	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	3.92e-05	0.00374	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	3.92e-05	0.00374	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	3.87e-05	0.00368	CbGpPWpGaD
Riluzole—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	3.87e-05	0.00368	CbGpPWpGaD
Riluzole—SLC7A11—NRF2 pathway—TGFB1—multiple sclerosis	3.71e-05	0.00353	CbGpPWpGaD
Riluzole—SLC7A11—SLC-mediated transmembrane transport—ALB—multiple sclerosis	3.69e-05	0.00352	CbGpPWpGaD
Riluzole—Hypersensitivity—Mitoxantrone—multiple sclerosis	3.69e-05	0.000444	CcSEcCtD
Riluzole—Paraesthesia—Prednisolone—multiple sclerosis	3.68e-05	0.000443	CcSEcCtD
Riluzole—Tachycardia—Triamcinolone—multiple sclerosis	3.68e-05	0.000443	CcSEcCtD
Riluzole—Mental disorder—Prednisone—multiple sclerosis	3.68e-05	0.000443	CcSEcCtD
Riluzole—Nausea—Azathioprine—multiple sclerosis	3.68e-05	0.000442	CcSEcCtD
Riluzole—Tachycardia—Methylprednisolone—multiple sclerosis	3.67e-05	0.000442	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—PRNP—multiple sclerosis	3.67e-05	0.0035	CbGpPWpGaD
Riluzole—Skin disorder—Methylprednisolone—multiple sclerosis	3.66e-05	0.00044	CcSEcCtD
Riluzole—Malnutrition—Prednisone—multiple sclerosis	3.65e-05	0.00044	CcSEcCtD
Riluzole—Hyperhidrosis—Triamcinolone—multiple sclerosis	3.65e-05	0.000439	CcSEcCtD
Riluzole—Agranulocytosis—Methotrexate—multiple sclerosis	3.65e-05	0.000439	CcSEcCtD
Riluzole—Hyperhidrosis—Methylprednisolone—multiple sclerosis	3.64e-05	0.000438	CcSEcCtD
Riluzole—Convulsion—Dexamethasone—multiple sclerosis	3.63e-05	0.000437	CcSEcCtD
Riluzole—Convulsion—Betamethasone—multiple sclerosis	3.63e-05	0.000437	CcSEcCtD
Riluzole—Hypertension—Betamethasone—multiple sclerosis	3.62e-05	0.000436	CcSEcCtD
Riluzole—Hypertension—Dexamethasone—multiple sclerosis	3.62e-05	0.000436	CcSEcCtD
Riluzole—Asthenia—Mitoxantrone—multiple sclerosis	3.59e-05	0.000432	CcSEcCtD
Riluzole—Myalgia—Dexamethasone—multiple sclerosis	3.57e-05	0.00043	CcSEcCtD
Riluzole—Myalgia—Betamethasone—multiple sclerosis	3.57e-05	0.00043	CcSEcCtD
Riluzole—ABCG2—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	3.57e-05	0.0034	CbGpPWpGaD
Riluzole—Anxiety—Betamethasone—multiple sclerosis	3.56e-05	0.000428	CcSEcCtD
Riluzole—Anxiety—Dexamethasone—multiple sclerosis	3.56e-05	0.000428	CcSEcCtD
Riluzole—Discomfort—Dexamethasone—multiple sclerosis	3.53e-05	0.000425	CcSEcCtD
Riluzole—Discomfort—Betamethasone—multiple sclerosis	3.53e-05	0.000425	CcSEcCtD
Riluzole—Haemoglobin—Methotrexate—multiple sclerosis	3.53e-05	0.000424	CcSEcCtD
Riluzole—Hypotension—Methylprednisolone—multiple sclerosis	3.52e-05	0.000423	CcSEcCtD
Riluzole—Pain—Prednisolone—multiple sclerosis	3.51e-05	0.000422	CcSEcCtD
Riluzole—Haemorrhage—Methotrexate—multiple sclerosis	3.51e-05	0.000422	CcSEcCtD
Riluzole—Hepatitis—Methotrexate—multiple sclerosis	3.51e-05	0.000422	CcSEcCtD
Riluzole—Pharyngitis—Methotrexate—multiple sclerosis	3.48e-05	0.000419	CcSEcCtD
Riluzole—Urinary tract disorder—Methotrexate—multiple sclerosis	3.46e-05	0.000417	CcSEcCtD
Riluzole—Urethral disorder—Methotrexate—multiple sclerosis	3.44e-05	0.000414	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	3.44e-05	0.000414	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	3.43e-05	0.000413	CcSEcCtD
Riluzole—Anaphylactic shock—Betamethasone—multiple sclerosis	3.42e-05	0.000412	CcSEcCtD
Riluzole—Oedema—Betamethasone—multiple sclerosis	3.42e-05	0.000412	CcSEcCtD
Riluzole—Oedema—Dexamethasone—multiple sclerosis	3.42e-05	0.000412	CcSEcCtD
Riluzole—Anaphylactic shock—Dexamethasone—multiple sclerosis	3.42e-05	0.000412	CcSEcCtD
Riluzole—Diarrhoea—Mitoxantrone—multiple sclerosis	3.42e-05	0.000412	CcSEcCtD
Riluzole—Insomnia—Triamcinolone—multiple sclerosis	3.41e-05	0.000411	CcSEcCtD
Riluzole—Insomnia—Methylprednisolone—multiple sclerosis	3.41e-05	0.00041	CcSEcCtD
Riluzole—Infection—Dexamethasone—multiple sclerosis	3.4e-05	0.000409	CcSEcCtD
Riluzole—Infection—Betamethasone—multiple sclerosis	3.4e-05	0.000409	CcSEcCtD
Riluzole—Ill-defined disorder—Prednisone—multiple sclerosis	3.39e-05	0.000408	CcSEcCtD
Riluzole—Paraesthesia—Triamcinolone—multiple sclerosis	3.39e-05	0.000408	CcSEcCtD
Riluzole—Feeling abnormal—Prednisolone—multiple sclerosis	3.38e-05	0.000407	CcSEcCtD
Riluzole—Paraesthesia—Methylprednisolone—multiple sclerosis	3.38e-05	0.000407	CcSEcCtD
Riluzole—Anaemia—Prednisone—multiple sclerosis	3.38e-05	0.000406	CcSEcCtD
Riluzole—Shock—Dexamethasone—multiple sclerosis	3.37e-05	0.000405	CcSEcCtD
Riluzole—Shock—Betamethasone—multiple sclerosis	3.37e-05	0.000405	CcSEcCtD
Riluzole—Dyspnoea—Triamcinolone—multiple sclerosis	3.36e-05	0.000405	CcSEcCtD
Riluzole—Nervous system disorder—Dexamethasone—multiple sclerosis	3.36e-05	0.000404	CcSEcCtD
Riluzole—Nervous system disorder—Betamethasone—multiple sclerosis	3.36e-05	0.000404	CcSEcCtD
Riluzole—Agitation—Prednisone—multiple sclerosis	3.36e-05	0.000404	CcSEcCtD
Riluzole—Thrombocytopenia—Dexamethasone—multiple sclerosis	3.35e-05	0.000403	CcSEcCtD
Riluzole—Thrombocytopenia—Betamethasone—multiple sclerosis	3.35e-05	0.000403	CcSEcCtD
Riluzole—Tachycardia—Dexamethasone—multiple sclerosis	3.34e-05	0.000402	CcSEcCtD
Riluzole—Tachycardia—Betamethasone—multiple sclerosis	3.34e-05	0.000402	CcSEcCtD
Riluzole—Angioedema—Prednisone—multiple sclerosis	3.34e-05	0.000402	CcSEcCtD
Riluzole—Dyspepsia—Triamcinolone—multiple sclerosis	3.32e-05	0.0004	CcSEcCtD
Riluzole—Erythema multiforme—Methotrexate—multiple sclerosis	3.32e-05	0.000399	CcSEcCtD
Riluzole—Dyspepsia—Methylprednisolone—multiple sclerosis	3.31e-05	0.000399	CcSEcCtD
Riluzole—Hyperhidrosis—Betamethasone—multiple sclerosis	3.31e-05	0.000398	CcSEcCtD
Riluzole—Hyperhidrosis—Dexamethasone—multiple sclerosis	3.31e-05	0.000398	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	3.3e-05	0.00315	CbGpPWpGaD
Riluzole—Malaise—Prednisone—multiple sclerosis	3.29e-05	0.000397	CcSEcCtD
Riluzole—Vertigo—Prednisone—multiple sclerosis	3.28e-05	0.000395	CcSEcCtD
Riluzole—Eye disorder—Methotrexate—multiple sclerosis	3.28e-05	0.000395	CcSEcCtD
Riluzole—Syncope—Prednisone—multiple sclerosis	3.28e-05	0.000394	CcSEcCtD
Riluzole—Anorexia—Dexamethasone—multiple sclerosis	3.26e-05	0.000393	CcSEcCtD
Riluzole—Anorexia—Betamethasone—multiple sclerosis	3.26e-05	0.000393	CcSEcCtD
Riluzole—Urticaria—Prednisolone—multiple sclerosis	3.26e-05	0.000392	CcSEcCtD
Riluzole—Cardiac disorder—Methotrexate—multiple sclerosis	3.26e-05	0.000392	CcSEcCtD
Riluzole—Fatigue—Triamcinolone—multiple sclerosis	3.25e-05	0.000392	CcSEcCtD
Riluzole—Fatigue—Methylprednisolone—multiple sclerosis	3.25e-05	0.000391	CcSEcCtD
Riluzole—Pain—Triamcinolone—multiple sclerosis	3.23e-05	0.000388	CcSEcCtD
Riluzole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	3.22e-05	0.00307	CbGpPWpGaD
Riluzole—CYP1A1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	3.21e-05	0.00306	CbGpPWpGaD
Riluzole—Loss of consciousness—Prednisone—multiple sclerosis	3.21e-05	0.000386	CcSEcCtD
Riluzole—Hypotension—Betamethasone—multiple sclerosis	3.2e-05	0.000385	CcSEcCtD
Riluzole—Hypotension—Dexamethasone—multiple sclerosis	3.2e-05	0.000385	CcSEcCtD
Riluzole—Angiopathy—Methotrexate—multiple sclerosis	3.18e-05	0.000383	CcSEcCtD
Riluzole—Vomiting—Mitoxantrone—multiple sclerosis	3.18e-05	0.000383	CcSEcCtD
Riluzole—Immune system disorder—Methotrexate—multiple sclerosis	3.17e-05	0.000381	CcSEcCtD
Riluzole—Convulsion—Prednisone—multiple sclerosis	3.17e-05	0.000381	CcSEcCtD
Riluzole—Mediastinal disorder—Methotrexate—multiple sclerosis	3.16e-05	0.00038	CcSEcCtD
Riluzole—Hypertension—Prednisone—multiple sclerosis	3.15e-05	0.00038	CcSEcCtD
Riluzole—Rash—Mitoxantrone—multiple sclerosis	3.15e-05	0.00038	CcSEcCtD
Riluzole—Dermatitis—Mitoxantrone—multiple sclerosis	3.15e-05	0.000379	CcSEcCtD
Riluzole—Chills—Methotrexate—multiple sclerosis	3.15e-05	0.000379	CcSEcCtD
Riluzole—Headache—Mitoxantrone—multiple sclerosis	3.13e-05	0.000377	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	3.12e-05	0.000375	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	3.12e-05	0.000375	CcSEcCtD
Riluzole—Arthralgia—Prednisone—multiple sclerosis	3.11e-05	0.000374	CcSEcCtD
Riluzole—Myalgia—Prednisone—multiple sclerosis	3.11e-05	0.000374	CcSEcCtD
Riluzole—Feeling abnormal—Triamcinolone—multiple sclerosis	3.11e-05	0.000374	CcSEcCtD
Riluzole—Feeling abnormal—Methylprednisolone—multiple sclerosis	3.1e-05	0.000373	CcSEcCtD
Riluzole—Anxiety—Prednisone—multiple sclerosis	3.1e-05	0.000373	CcSEcCtD
Riluzole—Alopecia—Methotrexate—multiple sclerosis	3.1e-05	0.000373	CcSEcCtD
Riluzole—Insomnia—Betamethasone—multiple sclerosis	3.1e-05	0.000373	CcSEcCtD
Riluzole—Insomnia—Dexamethasone—multiple sclerosis	3.1e-05	0.000373	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	3.09e-05	0.000372	CcSEcCtD
Riluzole—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	3.08e-05	0.000371	CcSEcCtD
Riluzole—Paraesthesia—Dexamethasone—multiple sclerosis	3.07e-05	0.00037	CcSEcCtD
Riluzole—Paraesthesia—Betamethasone—multiple sclerosis	3.07e-05	0.00037	CcSEcCtD
Riluzole—Discomfort—Prednisone—multiple sclerosis	3.07e-05	0.00037	CcSEcCtD
Riluzole—Mental disorder—Methotrexate—multiple sclerosis	3.07e-05	0.00037	CcSEcCtD
Riluzole—Malnutrition—Methotrexate—multiple sclerosis	3.05e-05	0.000367	CcSEcCtD
Riluzole—Hypersensitivity—Prednisolone—multiple sclerosis	3.02e-05	0.000364	CcSEcCtD
Riluzole—Dyspepsia—Dexamethasone—multiple sclerosis	3.01e-05	0.000363	CcSEcCtD
Riluzole—Dyspepsia—Betamethasone—multiple sclerosis	3.01e-05	0.000363	CcSEcCtD
Riluzole—SCN5A—L1CAM interactions—MAPK1—multiple sclerosis	3.01e-05	0.00287	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—IL2RA—multiple sclerosis	3e-05	0.00286	CbGpPWpGaD
Riluzole—Urticaria—Triamcinolone—multiple sclerosis	3e-05	0.000361	CcSEcCtD
Riluzole—Urticaria—Methylprednisolone—multiple sclerosis	2.99e-05	0.00036	CcSEcCtD
Riluzole—Dysgeusia—Methotrexate—multiple sclerosis	2.99e-05	0.00036	CcSEcCtD
Riluzole—Body temperature increased—Triamcinolone—multiple sclerosis	2.98e-05	0.000359	CcSEcCtD
Riluzole—Anaphylactic shock—Prednisone—multiple sclerosis	2.98e-05	0.000359	CcSEcCtD
Riluzole—Oedema—Prednisone—multiple sclerosis	2.98e-05	0.000359	CcSEcCtD
Riluzole—Abdominal pain—Methylprednisolone—multiple sclerosis	2.98e-05	0.000358	CcSEcCtD
Riluzole—Decreased appetite—Betamethasone—multiple sclerosis	2.98e-05	0.000358	CcSEcCtD
Riluzole—Decreased appetite—Dexamethasone—multiple sclerosis	2.98e-05	0.000358	CcSEcCtD
Riluzole—Nausea—Mitoxantrone—multiple sclerosis	2.97e-05	0.000358	CcSEcCtD
Riluzole—Infection—Prednisone—multiple sclerosis	2.96e-05	0.000357	CcSEcCtD
Riluzole—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	2.96e-05	0.000356	CcSEcCtD
Riluzole—Gastrointestinal disorder—Betamethasone—multiple sclerosis	2.96e-05	0.000356	CcSEcCtD
Riluzole—Back pain—Methotrexate—multiple sclerosis	2.95e-05	0.000355	CcSEcCtD
Riluzole—Fatigue—Dexamethasone—multiple sclerosis	2.95e-05	0.000355	CcSEcCtD
Riluzole—Fatigue—Betamethasone—multiple sclerosis	2.95e-05	0.000355	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	2.95e-05	0.00281	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	2.94e-05	0.0028	CbGpPWpGaD
Riluzole—Shock—Prednisone—multiple sclerosis	2.93e-05	0.000353	CcSEcCtD
Riluzole—Pain—Dexamethasone—multiple sclerosis	2.93e-05	0.000352	CcSEcCtD
Riluzole—Pain—Betamethasone—multiple sclerosis	2.93e-05	0.000352	CcSEcCtD
Riluzole—Nervous system disorder—Prednisone—multiple sclerosis	2.92e-05	0.000352	CcSEcCtD
Riluzole—Tachycardia—Prednisone—multiple sclerosis	2.91e-05	0.00035	CcSEcCtD
Riluzole—Skin disorder—Prednisone—multiple sclerosis	2.9e-05	0.000349	CcSEcCtD
Riluzole—Hyperhidrosis—Prednisone—multiple sclerosis	2.88e-05	0.000347	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—PTPRC—multiple sclerosis	2.85e-05	0.00272	CbGpPWpGaD
Riluzole—Anorexia—Prednisone—multiple sclerosis	2.84e-05	0.000342	CcSEcCtD
Riluzole—Ill-defined disorder—Methotrexate—multiple sclerosis	2.83e-05	0.000341	CcSEcCtD
Riluzole—Anaemia—Methotrexate—multiple sclerosis	2.82e-05	0.00034	CcSEcCtD
Riluzole—Feeling abnormal—Dexamethasone—multiple sclerosis	2.82e-05	0.00034	CcSEcCtD
Riluzole—Feeling abnormal—Betamethasone—multiple sclerosis	2.82e-05	0.00034	CcSEcCtD
Riluzole—Gastrointestinal pain—Betamethasone—multiple sclerosis	2.8e-05	0.000337	CcSEcCtD
Riluzole—Gastrointestinal pain—Dexamethasone—multiple sclerosis	2.8e-05	0.000337	CcSEcCtD
Riluzole—Hypersensitivity—Triamcinolone—multiple sclerosis	2.78e-05	0.000335	CcSEcCtD
Riluzole—Hypersensitivity—Methylprednisolone—multiple sclerosis	2.77e-05	0.000334	CcSEcCtD
Riluzole—Malaise—Methotrexate—multiple sclerosis	2.75e-05	0.000331	CcSEcCtD
Riluzole—Vertigo—Methotrexate—multiple sclerosis	2.74e-05	0.00033	CcSEcCtD
Riluzole—Leukopenia—Methotrexate—multiple sclerosis	2.73e-05	0.000329	CcSEcCtD
Riluzole—Urticaria—Dexamethasone—multiple sclerosis	2.72e-05	0.000327	CcSEcCtD
Riluzole—Urticaria—Betamethasone—multiple sclerosis	2.72e-05	0.000327	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Prednisone—multiple sclerosis	2.72e-05	0.000327	CcSEcCtD
Riluzole—Dizziness—Prednisolone—multiple sclerosis	2.71e-05	0.000327	CcSEcCtD
Riluzole—Asthenia—Triamcinolone—multiple sclerosis	2.71e-05	0.000326	CcSEcCtD
Riluzole—Abdominal pain—Dexamethasone—multiple sclerosis	2.71e-05	0.000326	CcSEcCtD
Riluzole—Abdominal pain—Betamethasone—multiple sclerosis	2.71e-05	0.000326	CcSEcCtD
Riluzole—Body temperature increased—Betamethasone—multiple sclerosis	2.71e-05	0.000326	CcSEcCtD
Riluzole—Body temperature increased—Dexamethasone—multiple sclerosis	2.71e-05	0.000326	CcSEcCtD
Riluzole—ABCG2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	2.7e-05	0.00258	CbGpPWpGaD
Riluzole—Asthenia—Methylprednisolone—multiple sclerosis	2.7e-05	0.000325	CcSEcCtD
Riluzole—Insomnia—Prednisone—multiple sclerosis	2.7e-05	0.000325	CcSEcCtD
Riluzole—SCN5A—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	2.68e-05	0.00256	CbGpPWpGaD
Riluzole—Paraesthesia—Prednisone—multiple sclerosis	2.68e-05	0.000322	CcSEcCtD
Riluzole—Pruritus—Triamcinolone—multiple sclerosis	2.67e-05	0.000321	CcSEcCtD
Riluzole—Cough—Methotrexate—multiple sclerosis	2.66e-05	0.000321	CcSEcCtD
Riluzole—Pruritus—Methylprednisolone—multiple sclerosis	2.66e-05	0.000321	CcSEcCtD
Riluzole—Convulsion—Methotrexate—multiple sclerosis	2.65e-05	0.000318	CcSEcCtD
Riluzole—Dyspepsia—Prednisone—multiple sclerosis	2.62e-05	0.000316	CcSEcCtD
Riluzole—CYP1A1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.6e-05	0.00248	CbGpPWpGaD
Riluzole—Arthralgia—Methotrexate—multiple sclerosis	2.6e-05	0.000313	CcSEcCtD
Riluzole—Myalgia—Methotrexate—multiple sclerosis	2.6e-05	0.000313	CcSEcCtD
Riluzole—Chest pain—Methotrexate—multiple sclerosis	2.6e-05	0.000313	CcSEcCtD
Riluzole—Decreased appetite—Prednisone—multiple sclerosis	2.59e-05	0.000312	CcSEcCtD
Riluzole—Rash—Prednisolone—multiple sclerosis	2.59e-05	0.000311	CcSEcCtD
Riluzole—Dermatitis—Prednisolone—multiple sclerosis	2.58e-05	0.000311	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	2.58e-05	0.000311	CcSEcCtD
Riluzole—Diarrhoea—Methylprednisolone—multiple sclerosis	2.58e-05	0.00031	CcSEcCtD
Riluzole—Fatigue—Prednisone—multiple sclerosis	2.57e-05	0.000309	CcSEcCtD
Riluzole—Headache—Prednisolone—multiple sclerosis	2.57e-05	0.000309	CcSEcCtD
Riluzole—Discomfort—Methotrexate—multiple sclerosis	2.57e-05	0.000309	CcSEcCtD
Riluzole—Constipation—Prednisone—multiple sclerosis	2.55e-05	0.000307	CcSEcCtD
Riluzole—Confusional state—Methotrexate—multiple sclerosis	2.51e-05	0.000302	CcSEcCtD
Riluzole—Dizziness—Triamcinolone—multiple sclerosis	2.5e-05	0.0003	CcSEcCtD
Riluzole—Anaphylactic shock—Methotrexate—multiple sclerosis	2.49e-05	0.0003	CcSEcCtD
Riluzole—Dizziness—Methylprednisolone—multiple sclerosis	2.49e-05	0.0003	CcSEcCtD
Riluzole—Infection—Methotrexate—multiple sclerosis	2.48e-05	0.000298	CcSEcCtD
Riluzole—Feeling abnormal—Prednisone—multiple sclerosis	2.46e-05	0.000296	CcSEcCtD
Riluzole—Asthenia—Dexamethasone—multiple sclerosis	2.46e-05	0.000296	CcSEcCtD
Riluzole—Asthenia—Betamethasone—multiple sclerosis	2.46e-05	0.000296	CcSEcCtD
Riluzole—Nervous system disorder—Methotrexate—multiple sclerosis	2.44e-05	0.000294	CcSEcCtD
Riluzole—Thrombocytopenia—Methotrexate—multiple sclerosis	2.44e-05	0.000294	CcSEcCtD
Riluzole—Gastrointestinal pain—Prednisone—multiple sclerosis	2.44e-05	0.000293	CcSEcCtD
Riluzole—Nausea—Prednisolone—multiple sclerosis	2.44e-05	0.000293	CcSEcCtD
Riluzole—Pruritus—Betamethasone—multiple sclerosis	2.42e-05	0.000292	CcSEcCtD
Riluzole—Pruritus—Dexamethasone—multiple sclerosis	2.42e-05	0.000292	CcSEcCtD
Riluzole—Skin disorder—Methotrexate—multiple sclerosis	2.42e-05	0.000291	CcSEcCtD
Riluzole—Hyperhidrosis—Methotrexate—multiple sclerosis	2.41e-05	0.00029	CcSEcCtD
Riluzole—Vomiting—Triamcinolone—multiple sclerosis	2.4e-05	0.000289	CcSEcCtD
Riluzole—Vomiting—Methylprednisolone—multiple sclerosis	2.39e-05	0.000288	CcSEcCtD
Riluzole—Rash—Triamcinolone—multiple sclerosis	2.38e-05	0.000286	CcSEcCtD
Riluzole—Dermatitis—Triamcinolone—multiple sclerosis	2.38e-05	0.000286	CcSEcCtD
Riluzole—Anorexia—Methotrexate—multiple sclerosis	2.38e-05	0.000286	CcSEcCtD
Riluzole—Rash—Methylprednisolone—multiple sclerosis	2.37e-05	0.000286	CcSEcCtD
Riluzole—Dermatitis—Methylprednisolone—multiple sclerosis	2.37e-05	0.000285	CcSEcCtD
Riluzole—Urticaria—Prednisone—multiple sclerosis	2.37e-05	0.000285	CcSEcCtD
Riluzole—Headache—Triamcinolone—multiple sclerosis	2.36e-05	0.000285	CcSEcCtD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	2.36e-05	0.00225	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	2.36e-05	0.00225	CbGpPWpGaD
Riluzole—Headache—Methylprednisolone—multiple sclerosis	2.36e-05	0.000284	CcSEcCtD
Riluzole—Abdominal pain—Prednisone—multiple sclerosis	2.36e-05	0.000284	CcSEcCtD
Riluzole—Body temperature increased—Prednisone—multiple sclerosis	2.36e-05	0.000284	CcSEcCtD
Riluzole—Diarrhoea—Betamethasone—multiple sclerosis	2.34e-05	0.000282	CcSEcCtD
Riluzole—Diarrhoea—Dexamethasone—multiple sclerosis	2.34e-05	0.000282	CcSEcCtD
Riluzole—Hypotension—Methotrexate—multiple sclerosis	2.33e-05	0.00028	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	2.3e-05	0.00219	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	2.29e-05	0.00218	CbGpPWpGaD
Riluzole—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	2.27e-05	0.000273	CcSEcCtD
Riluzole—Dizziness—Betamethasone—multiple sclerosis	2.26e-05	0.000273	CcSEcCtD
Riluzole—Dizziness—Dexamethasone—multiple sclerosis	2.26e-05	0.000273	CcSEcCtD
Riluzole—Insomnia—Methotrexate—multiple sclerosis	2.25e-05	0.000271	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	2.25e-05	0.00214	CbGpPWpGaD
Riluzole—Nausea—Triamcinolone—multiple sclerosis	2.24e-05	0.00027	CcSEcCtD
Riluzole—Paraesthesia—Methotrexate—multiple sclerosis	2.24e-05	0.000269	CcSEcCtD
Riluzole—Nausea—Methylprednisolone—multiple sclerosis	2.24e-05	0.000269	CcSEcCtD
Riluzole—Dyspnoea—Methotrexate—multiple sclerosis	2.22e-05	0.000267	CcSEcCtD
Riluzole—Somnolence—Methotrexate—multiple sclerosis	2.22e-05	0.000267	CcSEcCtD
Riluzole—ABCG2—Metabolism—SRM—multiple sclerosis	2.2e-05	0.0021	CbGpPWpGaD
Riluzole—Hypersensitivity—Prednisone—multiple sclerosis	2.2e-05	0.000264	CcSEcCtD
Riluzole—Dyspepsia—Methotrexate—multiple sclerosis	2.19e-05	0.000264	CcSEcCtD
Riluzole—Vomiting—Dexamethasone—multiple sclerosis	2.18e-05	0.000262	CcSEcCtD
Riluzole—Vomiting—Betamethasone—multiple sclerosis	2.18e-05	0.000262	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—ALB—multiple sclerosis	2.17e-05	0.00207	CbGpPWpGaD
Riluzole—Decreased appetite—Methotrexate—multiple sclerosis	2.17e-05	0.000261	CcSEcCtD
Riluzole—Rash—Dexamethasone—multiple sclerosis	2.16e-05	0.00026	CcSEcCtD
Riluzole—Rash—Betamethasone—multiple sclerosis	2.16e-05	0.00026	CcSEcCtD
Riluzole—Dermatitis—Dexamethasone—multiple sclerosis	2.16e-05	0.00026	CcSEcCtD
Riluzole—Dermatitis—Betamethasone—multiple sclerosis	2.16e-05	0.00026	CcSEcCtD
Riluzole—Gastrointestinal disorder—Methotrexate—multiple sclerosis	2.15e-05	0.000259	CcSEcCtD
Riluzole—Fatigue—Methotrexate—multiple sclerosis	2.15e-05	0.000259	CcSEcCtD
Riluzole—Headache—Betamethasone—multiple sclerosis	2.14e-05	0.000258	CcSEcCtD
Riluzole—Headache—Dexamethasone—multiple sclerosis	2.14e-05	0.000258	CcSEcCtD
Riluzole—Asthenia—Prednisone—multiple sclerosis	2.14e-05	0.000257	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	2.14e-05	0.00204	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	2.14e-05	0.00204	CbGpPWpGaD
Riluzole—ABCG2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	2.14e-05	0.00204	CbGpPWpGaD
Riluzole—Pain—Methotrexate—multiple sclerosis	2.13e-05	0.000256	CcSEcCtD
Riluzole—Pruritus—Prednisone—multiple sclerosis	2.11e-05	0.000254	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	2.11e-05	0.00201	CbGpPWpGaD
Riluzole—Feeling abnormal—Methotrexate—multiple sclerosis	2.05e-05	0.000247	CcSEcCtD
Riluzole—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	2.05e-05	0.00195	CbGpPWpGaD
Riluzole—Diarrhoea—Prednisone—multiple sclerosis	2.04e-05	0.000246	CcSEcCtD
Riluzole—Gastrointestinal pain—Methotrexate—multiple sclerosis	2.04e-05	0.000245	CcSEcCtD
Riluzole—Nausea—Betamethasone—multiple sclerosis	2.03e-05	0.000245	CcSEcCtD
Riluzole—Nausea—Dexamethasone—multiple sclerosis	2.03e-05	0.000245	CcSEcCtD
Riluzole—Urticaria—Methotrexate—multiple sclerosis	1.98e-05	0.000238	CcSEcCtD
Riluzole—Dizziness—Prednisone—multiple sclerosis	1.97e-05	0.000237	CcSEcCtD
Riluzole—Abdominal pain—Methotrexate—multiple sclerosis	1.97e-05	0.000237	CcSEcCtD
Riluzole—Body temperature increased—Methotrexate—multiple sclerosis	1.97e-05	0.000237	CcSEcCtD
Riluzole—SCN5A—SIDS Susceptibility Pathways—TNF—multiple sclerosis	1.95e-05	0.00185	CbGpPWpGaD
Riluzole—Vomiting—Prednisone—multiple sclerosis	1.9e-05	0.000228	CcSEcCtD
Riluzole—ABCG2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	1.89e-05	0.0018	CbGpPWpGaD
Riluzole—Rash—Prednisone—multiple sclerosis	1.88e-05	0.000226	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	1.88e-05	0.00179	CbGpPWpGaD
Riluzole—Dermatitis—Prednisone—multiple sclerosis	1.88e-05	0.000226	CcSEcCtD
Riluzole—SLC7A11—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.88e-05	0.00179	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	1.87e-05	0.00178	CbGpPWpGaD
Riluzole—Headache—Prednisone—multiple sclerosis	1.87e-05	0.000225	CcSEcCtD
Riluzole—Hypersensitivity—Methotrexate—multiple sclerosis	1.84e-05	0.000221	CcSEcCtD
Riluzole—SCN5A—Axon guidance—TYK2—multiple sclerosis	1.79e-05	0.0017	CbGpPWpGaD
Riluzole—Asthenia—Methotrexate—multiple sclerosis	1.79e-05	0.000215	CcSEcCtD
Riluzole—Nausea—Prednisone—multiple sclerosis	1.77e-05	0.000213	CcSEcCtD
Riluzole—Pruritus—Methotrexate—multiple sclerosis	1.76e-05	0.000212	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—IL2—multiple sclerosis	1.76e-05	0.00168	CbGpPWpGaD
Riluzole—Diarrhoea—Methotrexate—multiple sclerosis	1.71e-05	0.000205	CcSEcCtD
Riluzole—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	1.66e-05	0.00158	CbGpPWpGaD
Riluzole—Dizziness—Methotrexate—multiple sclerosis	1.65e-05	0.000198	CcSEcCtD
Riluzole—Vomiting—Methotrexate—multiple sclerosis	1.58e-05	0.000191	CcSEcCtD
Riluzole—Rash—Methotrexate—multiple sclerosis	1.57e-05	0.000189	CcSEcCtD
Riluzole—SCN5A—SIDS Susceptibility Pathways—IL6—multiple sclerosis	1.57e-05	0.0015	CbGpPWpGaD
Riluzole—Dermatitis—Methotrexate—multiple sclerosis	1.57e-05	0.000189	CcSEcCtD
Riluzole—Headache—Methotrexate—multiple sclerosis	1.56e-05	0.000188	CcSEcCtD
Riluzole—ABCG2—Metabolism—CYP24A1—multiple sclerosis	1.55e-05	0.00148	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—CYP27B1—multiple sclerosis	1.55e-05	0.00148	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	1.51e-05	0.00143	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	1.51e-05	0.00143	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—SRM—multiple sclerosis	1.49e-05	0.00142	CbGpPWpGaD
Riluzole—Nausea—Methotrexate—multiple sclerosis	1.48e-05	0.000178	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	1.46e-05	0.0014	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	1.46e-05	0.00139	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	1.43e-05	0.00136	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—GPC5—multiple sclerosis	1.42e-05	0.00135	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—MMP9—multiple sclerosis	1.41e-05	0.00134	CbGpPWpGaD
Riluzole—CYP1A1—Biological oxidations—POMC—multiple sclerosis	1.38e-05	0.00132	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—TGFB1—multiple sclerosis	1.37e-05	0.00131	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	1.36e-05	0.0013	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	1.36e-05	0.0013	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—MAPK1—multiple sclerosis	1.35e-05	0.00128	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—TYK2—multiple sclerosis	1.28e-05	0.00122	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—RRM1—multiple sclerosis	1.18e-05	0.00112	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—MAPK1—multiple sclerosis	1.14e-05	0.00109	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—CYP24A1—multiple sclerosis	1.05e-05	0.001	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—CYP27B1—multiple sclerosis	1.05e-05	0.001	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.03e-05	0.000979	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—MMP9—multiple sclerosis	1.01e-05	0.000958	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—GPC5—multiple sclerosis	9.62e-06	0.000916	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—SRM—multiple sclerosis	9.51e-06	0.000907	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—STAT3—multiple sclerosis	8.94e-06	0.000852	CbGpPWpGaD
Riluzole—CYP1A2—Biological oxidations—POMC—multiple sclerosis	8.82e-06	0.00084	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—IL6—multiple sclerosis	8.75e-06	0.000834	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—TGFB1—multiple sclerosis	8.29e-06	0.00079	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—MAPK1—multiple sclerosis	8.13e-06	0.000774	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—RRM1—multiple sclerosis	7.97e-06	0.000759	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—TNF—multiple sclerosis	7.74e-06	0.000737	CbGpPWpGaD
Riluzole—ABCG2—Transmembrane transport of small molecules—ALB—multiple sclerosis	6.8e-06	0.000648	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—BCHE—multiple sclerosis	6.76e-06	0.000644	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	6.7e-06	0.000639	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	6.7e-06	0.000639	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	6.55e-06	0.000624	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—IL6—multiple sclerosis	6.24e-06	0.000595	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.18e-06	0.000589	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—GPC5—multiple sclerosis	6.13e-06	0.000584	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.31e-06	0.000506	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—RRM1—multiple sclerosis	5.08e-06	0.000484	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	4.84e-06	0.000461	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—BCHE—multiple sclerosis	4.58e-06	0.000436	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—APOE—multiple sclerosis	4.07e-06	0.000388	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.94e-06	0.000376	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—POMC—multiple sclerosis	3.49e-06	0.000333	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.39e-06	0.000323	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—ALB—multiple sclerosis	3.19e-06	0.000304	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.09e-06	0.000294	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—BCHE—multiple sclerosis	2.92e-06	0.000278	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—APOE—multiple sclerosis	2.75e-06	0.000262	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—POMC—multiple sclerosis	2.36e-06	0.000225	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—ALB—multiple sclerosis	2.16e-06	0.000205	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—APOE—multiple sclerosis	1.76e-06	0.000167	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—POMC—multiple sclerosis	1.51e-06	0.000144	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—ALB—multiple sclerosis	1.37e-06	0.000131	CbGpPWpGaD
